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Abstract
Purpose Experimental and observational data link insulin,
insulin-like growth factor (IGF), and estrogens to
endometrial tumorigenesis. However, there are limited data
regarding insulin/IGF and sex hormone axes protein and
gene expression in normal endometrial tissues, and very
few studies have examined the impact of endometrial
cancer risk factors on endometrial tissue biology.
Methods We evaluated endometrial tissues from 77 pre-
menopausal and 30 postmenopausal women who under-
went hysterectomy for benign indications and had provided
epidemiological data. Endometrial tissue mRNA and pro-
tein levels were measured using quantitative real-time PCR
and immunohistochemistry, respectively.
Results In postmenopausal women, we observed higher
levels of phosphorylated IGF-I/insulin receptor (pIGF1R/
pIR) in diabetic versus non-diabetic women (p value =0.02),
while women who reported regular nonsteroidal anti-inflam-
matory drug use versus no use had higher levels of insulin and
progesterone receptors (both p values B0.03). We also noted
differences in pIGF1R/pIR staining with OC use (post-
menopausal women only), and the proportion of estrogen
receptor-positive tissues varied by the number of live births
and PTEN status (premenopausal only) (p values B0.04).
Compared to premenopausal proliferative phase women,
postmenopausal women exhibited lower mRNA levels of
IGF1, but higher IGFBP1 and IGFBP3 expression (allpvalues
B0.004), and higher protein levels of the receptors for estro-
gen, insulin, and IGF-I (all p values B0.02). Conversely,
pIGF1R/pIR levelswerehigher in premenopausal proliferative
phase versus postmenopausal endometrium (p value =0.01).
Conclusions These results highlight links between
endometrial cancer risk factors and mechanistic factors that
may contribute to early events in the multistage process of
endometrial carcinogenesis.
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Introduction
Endometrial cancer is the most common gynecologic
malignancy worldwide with 319,605 new cases diagnosed
in 2012 [1]. Obesity has been consistently associated with
an increased risk of developing endometrial cancer [2, 3],
and approximately 40 % of new cases in developed
countries are thought to be attributable to a high body mass
index (BMI C 25 kg/m2) [4]. Other factors that are asso-
ciated with a higher risk of endometrial cancer include a
history of diabetes [5], postmenopausal estrogen only
hormone use [6], an earlier age at menarche, later age of
menopause, and nulliparity [7, 8]. Factors that appear to
lower endometrial cancer risk include use of oral contra-
ceptives (OCs) [7, 8] and aspirin but not other nonsteroidal
anti-inflammatory drugs (NSAIDs) [9].
Few studies have examined the impact of endometrial
cancer risk factors, such as obesity, diabetes, and nonuse of
aspirin on the insulin/IGF and sex hormone axes in normal
endometrial tissues. In an earlier study, Argenta et al. [10]
examined hormone receptor expression in 46 obese women
who underwent endometrial tissue sampling before and
after bariatric surgery, and they observed similar patterns in
estrogen receptor (ER) immunohistochemical (IHC) stain-
ing following surgery. Based on the same normal endo-
metrium study population as the current study, Yang et al.
[11] assessed the relationship between PTEN loss and
exposure to endometrial cancer risk factors, and they
reported that NSAID use was associated with PTEN loss
while there was no difference in PTEN IHC staining for
other risk factors.
The biological mechanisms that underlie the association
of endometrial cancer with obesity, diabetes, and other risk
factors are not well understood. The insulin-like growth
factor (IGF) and sex hormone axes play important roles in
endometrial physiology [12, 13], and studies mainly
focusing on circulating insulin/IGF and sex hormone axes
suggest that these pathways are considerably dysregulated
in obesity and diabetes as well as in endometrial cancer
development [14]. Higher estrogen levels (that are not
simultaneously opposed by progesterone) have been asso-
ciated with a higher risk of developing endometrial cancer
[14, 15]. For example, in premenopausal women, ovarian
hyperandrogenism may lead to progesterone deficiency,
while in postmenopausal women, an increasing BMI has
been linked to higher circulating estrogen levels with adi-
pose tissue as the primary site of estrogen production from
androgen precursors [16, 17]. In a prospective study of 124
postmenopausal endometrial cancer cases from three
cohorts in New York, Northern Sweden, and Milan, there
was a 4.1-fold increase in endometrial cancer risk for
women in the top versus bottom quartile of estradiol levels
[18]. Obesity is also associated with higher serum insulin
levels [19], and several prospective cohort studies have
reported positive associations between circulating insulin
levels and endometrial cancer risk [20–22]. For example,
among postmenopausal nonusers of hormone therapy,
women who were classified in the highest versus lowest
quartile of insulin levels had a 2.3-fold increased risk of
developing endometrioid-type endometrial cancer [21].
In addition to the effects of circulating insulin/IGF
levels, insulin/IGF receptor activation is also influenced by
local tissue levels of IGF ligands as well as tissue levels of
IGF-binding proteins via their regulation of ligand
bioavailability. While insulin predominantly signals
through the insulin receptor (IR), IGFs bind to the IGF-I
receptor (IGF1R), as well as the IR, and hybrid IR/IGF1R
receptors [19, 23]. There is extensive crosstalk between the
sex hormone and insulin/IGF axes. The downstream
mitogenic and anti-apoptotic effects of estrogen and insu-
lin/IGF signaling converge on the AKT signaling pathway
whose activation is suppressed by the phosphatase activity
of the phosphatase and tensin homolog (PTEN) tumor
suppressor. In endometrial cancer, loss of heterozygosity at
the PTEN region has been reported in approximately 40 %
of cases and somatic PTEN mutations have been identified
in 37–83 % of tumors [24, 25]. Loss of PTEN function may
represent an important early event in endometrial car-
cinogenesis, which may be mechanistically linked to loss
of suppression of the mitogenic effects of estrogen, insulin,
and growth factors [11, 26]. In the current study, we
evaluated the tissue expression of IGF ligands (IGF1,
IGF2), IGF-binding proteins 1 and 3 (IGFBP1 and
IGFBP3), the tissue expression and activation of the insu-
lin/IGF receptors [IR, IGF1R, phosphorylated (activated)
IGF-I/insulin receptor (pIGF1R/pIR)], as well as the status
of the hormone receptors [ER, progesterone receptor (PR)],
and expression of PTEN in endometrial tissues from 77
premenopausal and 30 postmenopausal women who
underwent hysterectomy for benign indications.
Materials and methods
Study population
The study population was comprised of women who
underwent hysterectomy for benign indications such as
uterine prolapse and fibroids. Participants were recruited
from two studies, the Benign Reproductive Tissue Evalu-
ation (BRTE) and Einstein Normal Endometrium (ENE)
studies. The BRTE study included 150 consecutive mostly
premenopausal women who underwent a hysterectomy at
the Magee Women’s Hospital, Pittsburgh, Pennsylvania,
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USA, from 2006 to 2011 and who met the study’s eligi-
bility criteria. Specifically, these subjects were required to
be between the ages of 18–54 years, reported no use of
exogenous hormones within three months of enrollment,
and had not been diagnosed with any cancer when they had
their hysterectomy [11]. The ENE study sequentially
enrolled 50 postmenopausal women who consented to
participate as they presented for hysterectomy to treat
uterine prolapse at the Albert Einstein Hospital and Mon-
tefiore Medical Center, Bronx, New York, USA, between
2010 and 2014. Subjects could be of any age, but could not
have any cancer at the time of their hysterectomy. Patients
with uterine fibroids were eligible for the study, but only
tissues that were not adjacent to the fibroids (when present)
were sampled in case fibroid growth also interacts with
these pathways. The BRTE and ENE studies only included
subjects who did not have cancer at the time of hysterec-
tomy; therefore, endometrial cancer tissue samples were
unavailable for the current study. The current investigation
included all participants who completed the required
questionnaire, had known menopausal status and sufficient
endometrial tissues for the studies; this resulted in a study
population of 107 participants (n = 78 BRTE; n = 29
ENE). Informed consent was provided by all study par-
ticipants, and the study was approved by the Institutional
Review Board of the US National Cancer Institute and the
Albert Einstein College of Medicine and Montefiore
Medical Center.
Tissue collection
Endometrial tissues were collected during hysterectomy
surgery and immediately flash-frozen and/or fixed in 10 %
buffered formalin to embed in paraffin. All tissues were
frozen or formalin-fixed within 30–60 min of operative
removal when possible.
Lifestyle questionnaire
All participants completed a self-administered study-
specific questionnaire that included questions on general
medical history, reproductive history (e.g., parity, ages at
menarche, and menopause), use of OCs and post-
menopausal hormone therapies, smoking, height, weight,
and NSAID use. NSAID use was defined as any use of
aspirin or ibuprofen in the past 12 months (BRTE) or
regular use of aspirin, acetaminophen, or other anti-in-
flammatory drugs such as Ibuprofen, Naproxen, Piroxicam,
Indomethacin, Sulindac, or COX-2 inhibitors, e.g., Cele-
coxib or Rofecoxib (ENE). In analyses of aspirin versus
non-aspirin NSAIDs, very few participants were exclusive
aspirin users. Therefore, the aspirin user category included
participants who reported any aspirin use (with or without
non-aspirin NSAID use). All of the ENE study participants
were postmenopausal at enrollment. In the BRTE study,
participants were asked about their menstrual cycle pattern,
and they were classified as premenopausal if they reported
regular or irregular monthly periods in the 12 months prior
to enrollment.
Laboratory assays
IHC staining was carried out for: IGF1R; IR; pIGF1R/pIR;
ER a; and PR. IHC staining was performed on 5-lm sec-
tions of formalin-fixed paraffin-embedded endometrial
tissues from 106 participants (n = 78 BRTE; n = 28
ENE). Tissue sections were deparaffinized using xylene
and graded alcohols. Antigen retrieval was performed in
Target Retrieval Solution, pH 6.1 (Dako, Inc., Carpinteria,
CA, USA) at 95 C for 30 min. After cooling at room
temperature, slides were rinsed in Tris-buffered saline
(TBS), pH 7.5 (0.02 M Tris/Tris-HCl and 0.15 M NaCl).
Endogenous peroxidase was quenched with peroxidase
blocking reagent (Dako, Inc.) for 10 min. After rinsing
with TBS, blocking solution was applied for 30 min at
room temperature, and then the primary antibody solution
was applied. IHC conditions for the primary antibodies are
summarized in Supplementary Table 1. Slides were
washed three times with TBS-T (0.1 % Tween 20), then
incubated with the appropriate secondary antibody (EnVi-
sionTM ? Kits, Dako, Inc.). After 39 washes with TBS-T,
slides were incubated with diaminobenzidine chromogen
solution. Slides were rinsed with water and counterstained
with hematoxylin, dehydrated through graded alcohols,
absolute ethanol, and xylene, then coverslipped with
mounting medium. Positive control tissues and negative
control slides were stained in parallel for all IHC assays.
The slides were scored by the study pathologist (K.W.).
IHC staining scores were estimated separately for glandu-
lar and stromal cells. For IGF1R, pIGF1R/pIR, and IR,
both nuclear and cytoplasmic cellular localizations were
evaluated, while for ER and PR only nuclear staining was
assessed. Nuclear localization of the IR and IGF1R has
been observed previously and may have functional signif-
icance [27]. PTEN immunostaining was measured for 81
participants (n = 65 BRTE; n = 16 ENE) using a vali-
dated monoclonal antibody that can detect PTEN loss (i.e.,
PTEN-null, or loss of PTEN protein expression in micro-
scopically normal endometrial glands) [28] (Supplemen-
tary Table 1). PTEN staining was scored by a second study
pathologist (M.E.S.) who at the same time reviewed the
slides to classify the menstrual cycle phase (proliferative,
secretory, or other) for the BRTE cases at their time of
surgery.
Gene expression (mRNA levels) of IGF1, IGF2,
IGFBP1, and IGFBP3 was measured with qPCR using
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investigator-validated primers (Supplementary Table 2) in
the subset of patients with adequate frozen tissues available
(i.e., good quality RNA was obtained) (n = 37 BRTE;
n = 26 ENE). To extract RNA, whole frozen tissues were
pulverized in a tissueTUBE bag (Covaris, Woburn, MA,
USA) using a Covaris CryoPrep and then homogenized in
Buffer RLT (Qiagen, Valencia, CA, USA) using a Covaris
adaptive focused acoustics tissue disrupter. The Qiagen
AllPrep kit was used following the manufacturer’s
instructions for isolation of RNA and DNA. The RNA
concentration and purity was measured using a Nanodrop
spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA), and RNA integrity was evaluated with the
Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA).
RNA quality was uniformly excellent and met the fol-
lowing criteria: Nanodrop, 260/280 ratio [1.8; Agilent
Bioanalyzer, RIN[ 6. Following RNA extraction and
purification, complementary DNA was synthesized from
1 lg of total RNA using the SuperScript VILO cDNA
Synthesis Kit (Life Technologies, Grand Island, NY,
USA). Quantitative real-time PCRs were carried out using
investigator-validated primers for the target genes [29]
(Supplementary Table 2), and PowerSYBR Green (Life
Technologies) detection according to the manufacturer’s
recommendations. The reaction scale was adjusted for use
in 384-well plates on the Applied Biosystems 7900HT Fast
Real-Time PCR System (Life Technologies). Target gene
expression was internally normalized to the expression of
the housekeeping gene peptidylprolyl isomerase B (PPIB),
and each reaction was run in triplicate on the same plate.
Each assay plate included two reactions that omit either the
mRNA template or the reverse transcriptase enzyme to
exclude the possibility of contamination. RNA concentra-
tions were provided as raw Ct values, and expression
scores were calculated using 2^(-deltaCt) 9 1,000 [arbi-
trary units/scaling factor] [30].
Statistical analysis
For IHC data, the staining intensity in different areas of the
section was assessed using standardized ranges and allo-
cated a value of 0 (none), 1 (weak), 2 (moderate), or 3
(strong). The percentage of cells that stained positive in
five 409 fields was estimated, and the percentage of pos-
itive cells was multiplied by the intensity value to calculate
the H-score with a maximum value of 300. For ER and PR
staining, a cutoff H-score C75 was used to differentiate
between positive and negative staining as previously
described [31]. For consistency with a previous study [32],
endometrial tissues were classified as positive for IGF1R,
pIGF1R/pIR, and IR staining if the H-score was [20
(equivalent to a 2? staining intensity in[10 % positive
cells). PTEN staining was scored as wild type (PTEN
present) or PTEN-null.
We evaluated measures of protein and gene expression
levels in endometrial tissues across binary categories of
endometrial cancer risk factors as follows: BMI (di-
chotomized at the median, 28.3 kg/m2), self-reported dia-
betes (no, yes), smoking status (never smoked, former/
current smoker), ever pregnant (no, yes), number of chil-
dren among women with C1 live birth (1–2, C3), OC use
(never, ever), age at menarche (age\12 years, C12), any
NSAID use (no, yes), and NSAID type (among ever
NSAID users; aspirin, non-aspirin only). To avoid possible
confounding by menopausal status and study site, all risk
factor comparisons were restricted to premenopausal or
postmenopausal subjects. For premenopausal BRTE par-
ticipants, protein or gene expression levels were addition-
ally examined in relation to menstrual cycle phase
(proliferative, secretory) at the time of hysterectomy. In the
comparison by menopausal status, we evaluated pre-
menopausal (proliferative phase only) versus post-
menopausal women in order to assess insulin/IGF and sex
hormone axes in a more uniform premenopausal group who
were likely exposed to higher estrogen levels at the time of
their hysterectomy.
We tested whether there were differences in protein
levels in endometrial tissues according to risk factor cate-
gories using Fisher’s exact tests, while gene expression
levels (assessed continuously) were compared across risk
factor categories using Wilcoxon tests. Analyses were only
undertaken if there were n C 5 samples in each comparison
category. All analyses were carried out separately accord-
ing to menopausal status. Statistical tests were two-sided,
and a p value\0.05 was considered statistically significant.
Statistical analyses were performed using R version 3.1.1
[33].
Results
The BRTE and ENE studies included mostly pre-
menopausal and postmenopausal participants, respectively;
therefore, BRTE participants were younger (BRTE mean
age = 43.4 years vs. ENE mean = 60.9 years) (Table 1).
BRTE versus ENE participants, respectively, were more
likely to have ever used OCs (73 vs. 48 %) and NSAIDs
(69 vs. 48 %), had a longer duration of OC use (8.9 years
vs. 5.2), and were more likely to be current/former smokers
(50 vs. 21 %). The proportion of ever-pregnant women was
similar across studies; however, BRTE participants had
fewer live births (BRTE mean = 1.8 live births vs. ENE
mean = 2.6).
Cancer Causes Control
123
Evaluation of endometrial cancer risk factors
in relation to endometrial tissue protein and mRNA
levels of insulin/IGF and sex hormone axes
We examined endometrial cancer risk factors, namely
diabetes, BMI, smoking, NSAID use and type, age at
menarche, parity, OC use, and PTEN status in relation to
protein and gene expression levels in endometrial tissues.
There were significant differences in protein levels for
several of the risk factor comparisons; for example, post-
menopausal participants with diabetes had a higher fre-
quency of positive pIGF1R/pIR endometrial IHC staining
as compared to non-diabetics, respectively [pIGF1R/pIR
glandular cytoplasmic staining, 6/7 (86 %) positive vs.
5/18 (28 %) positive, p value = 0.02] (Table 2; Fig. 1a, b).
In the endometrium of postmenopausal NSAID users, we
observed that a higher proportion of subjects had positive
IHC staining for PR and IR, respectively, than nonusers of
NSAIDS [PR stromal staining, 13/13 (100 %) positive vs.
7/13 (54 %), p value =0.01, Fig. 1c, d; IR stromal nuclear
staining, 12/13 (92 %) positive vs. 6/13 (46 %), p value
=0.03, Fig. 1e, f]. Among parous premenopausal partici-
pants, a higher proportion of women with 3? live births
had ER-positive glandular cell staining (9/11 (82 %) pos-
itive) versus women with 1–2 children (15/34 (44 %)
positive, p value =0.04). In postmenopausal endometrial
tissues, there was a higher frequency of pIGF1R/pIR
nuclear glandular cell staining in OC users than in nonu-
sers, respectively (8/13 (62 %) positive vs. 2/13 (15 %),
p value =0.04). Lastly, we observed that a higher propor-
tion of participants had ER-positive glandular cell staining
in premenopausal endometrial tissues that were classified
as PTEN-null [8/8 (100 %) ER positive] versus PTEN
wild-type [21/44 (48 %) ER positive, p value =0.01]. For
the above-mentioned results, the IHC staining patterns
were restricted to either premenopausal or postmenopausal
tissues. Due to an insufficient number of cases, we were
unable to analyze diabetes in premenopausal women and
PTEN status and ever versus never pregnant in post-
menopausal women. For other proteins, the frequency of
positive/negative IHC staining did not vary according to
diabetes, NSAID use, parity, OC use, and PTEN status, and
none of the IHC proteins for any insulin/IGF or sex hor-
mone axis components differed in comparisons of BMI,
smoking status, age at menarche, ever versus never preg-
nant, and NSAID type (Supplementary Tables 3 and 4).
Table 1 Characteristics of the
BRTE and ENE study
populations
Study BRTE (n = 78) ENE (n = 29)
Age (years)a, mean (SD) 43.4 (6.0) 60.9 (8.0)
Duration OC usea,b (years), mean (SD) 8.9 (6.0) 5.2 (3.6)
Number of live birthsc, mean (SD) 1.8 (1.0) 2.6 (1.3)
Age at menarchea (years), mean (SD) 12.5 (1.8) 11.7 (1.6)
Body mass indexa (kg/m2), mean (SD) 29.4 (6.5) 29.3 (5.8)
Ever-use OCsa,d, n (%) 56 (73) 14 (48)
Ever pregnante, n (%) 68 (87) 26 (90)
Premenopausal, n (%) 77 (99) 0
Postmenopausal, n (%) 1 (1) 29 (100)
Postmenopausal hormone use, n (%) – 0
Any NSAID usea, n (%) 53 (69) 13 (48)
Current/former smoker, n (%) 39 (50) 6 (21)
Indication for hysterectomy
Adenomyosis, n (%) 5 (6) 0
Leiomyomata/fibroids, n (%) 25 (32) 3 (10)
Uterine prolapse, n (%) 1 (1) 24 (83)
Endometriosis, n (%) 12 (15) 0
Abnormal uterine bleeding, n (%) 9 (12) 0
1? above indications, n (%) 12 (15) 1 (3)
Other reason/missing, n (%) 14 (18) 1 (3)
a Missing data were B2.9 %
b Among ever users of OCs (use C1 year)
c Among parous women
d Ever-use OCs defined as use C1 year
e Ever pregnant includes live births, still births, and miscarriages
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We did not observe differences in IGF axis gene
expression levels in comparisons of the risk factor cate-
gories (data not shown); however, selected comparisons
could not be carried out due to limited numbers (diabetes in
premenopause, ever versus never pregnant in post-
menopause, or PTEN status irrespective of menopausal
status). We also were unable to evaluate protein and gene
expression levels across the risk factor categories when
stratifying by menstrual cycle phase among premenopausal
women due to the limited sample size.
Comparison of endometrial tissue protein
and mRNA levels for insulin/IGF and sex hormone
axes by menopausal status
In endometrial tissues, a higher proportion of subjects had
ER-positive staining by IHC in postmenopausal relative
to proliferative phase premenopausal participants, respec-
tively, for glandular tissue [26/29 (90 %) positive vs. 13/23
(57 %)] and in the stroma [21/29 (72 %) positive vs. 9/23
(39 %)], with both P values B0.02, whereas for PR (glan-
dular or stromal tissue) there was no difference in the fre-
quency of positive staining by menopausal status (Table 3).
A higher proportion of postmenopausal women versus pro-
liferative phase premenopausal participants, respectively,
had positive glandular cytoplasmic staining for the IR [25/28
(89 %) positive vs. 13/27 (48 %), p value =0.001] and
glandular nuclear staining for the IGF1R [18/28 (64 %)
positive vs. 4/26 (15 %), p value\0.001]. In contrast, there
was no difference in glandular nuclear staining for the
pIGF1R/pIR, and a lower proportion of postmenopausal
versus proliferative phase premenopausal participants,
respectively, had positive pIGF1R/pIR stromal nuclear
staining [4/26 (15 %) positive vs. 12/23 (52 %),
Table 2 Immunohistochemical
staining of insulin/IGF and sex
hormone axes in endometrium
in relation to endometrial cancer
risk factors
Premenopausal (n = 77) Postmenopausal (n = 29)
pIGF1R/pIR-c (gland)
Diabetes no 26/59 (44) 5/18 (28)
Diabetes yes N/A 6/7 (86)
p valuea – 0.02
pIGF1R/pIR-n (gland)
OC use nob 3/16 (19) 2/13 (15)
OC use yesb 9/42 (21) 8/13 (62)
p valuea 1.00 0.04
ER (gland)
Live birthsc 1–2 15/34 (44) 13/13 (100)
Live birthsc 3? 9/11 (82) 10/12 (83)
p valuea 0.04 0.22
ER (gland)
PTEN wild-type 21/44 (48) 14/14 (100)
PTEN-null 8/8 (100) 2/3 (67)
p valuea 0.01 –
IR-n (stroma)
NSAID use no 17/22 (77) 6/13 (46)
NSAID use yes 33/44 (75) 12/13 (92)
p valuea 1.00 0.03
PR (stroma)
NSAID use no 7/8 (88) 7/13 (54)
NSAID use yes 12/15 (80) 13/13 (100)
p valuea 1.00 0.01
Bold values indicate p\ 0.05
c cytoplasmic, ER estrogen receptor alpha, IR insulin receptor, n nuclear, N/A none available, pIGF1R/pIR
phosphorylated IGF1R/insulin receptor, PR progesterone receptor
Numbers in table refer to n positive/n total (% positive)
Numbers may not sum to total due to missing data on staining and/or the variable
a p value from Fisher’s exact test
b Ever use of OCs defined as use C1 year
c Restricted to women who had 1? live births
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respectively, p value =0.01]. There were also significant
differences in IGF axis mRNA levels in endometrial tissues
by menopausal status; compared with proliferative phase
premenopausal women, postmenopausal women had lower
expression of IGF1 and higher expression of IGFBP1 and
IGFBP3, whereas IGF2 gene expression levels did not differ
by menopausal status (Fig. 2; Supplementary Table 5).
In comparison with premenopausal women in the secre-
tory menstrual cycle phase, there was a higher proportion of
positive IR and pIGF1R/pIR protein expression in pre-
menopausal proliferative phase tissues [IR glandular nuclear
staining, 26/27 (96 %) positive vs. 18/24 (75 %), p value
=0.04 (data not shown); pIGF1R/pIR glandular cytoplasmic
staining, 15/24 (63 %) positive vs. 6/22 (27 %), p value
=0.02] (Supplementary Figure 1 a, b). In contrast, we
observed no difference in pIGF1R/pIR stromal cytoplasmic
staining or glandular/stromal nuclear pIGF1R/pIR staining
when comparing the proliferative versus secretory phase
endometrium (data not shown). There also were no signifi-
cant differences in the proportion of positive IHC staining
for other assayed proteins in comparisons of menstrual cycle
phase. In analyses of IGF axis mRNA levels, we observed
suggestively higher levels of IGFBP1 and IGF2 in secretory
versus proliferative phase premenopausal tissues (each
p value =0.06, Supplementary Figure 2).
Discussion
In this study of normal (benign) endometrial tissue in
which expression of the insulin/IGF and sex hormone axes
was evaluated in relation to endometrial cancer risk factors,
Fig. 1 Insulin/IGF and sex hormone axes protein expression in
endometrium in relation to diabetes status and NSAID use. a pIGF1R/
pIR glandular cytoplasmic staining is negative in this representative
endometrial tissue sample from a non-diabetic postmenopausal
patient. b pIGF1R/pIR glandular cytoplasmic staining is positive in
this representative endometrial tissue sample from a diabetic
postmenopausal patient. c PR stromal nuclear staining is low in this
representative endometrial tissue sample from a postmenopausal
patient who reported no NSAID use. This tissue also shows positive
nuclear PR glandular staining. d PR stromal nuclear staining is high in
this representative endometrial tissue sample from a postmenopausal
NSAID user. This tissue also shows positive nuclear PR glandular
staining. e IR stromal nuclear staining was negative in this
representative endometrial tissue sample from a postmenopausal
patient who reported no NSAID use. f IR stromal and glandular
nuclear staining was strongly positive in this representative endome-
trial tissue sample from a postmenopausal NSAID user. All images
shown are of equal magnification (9400) and scale (100-lm scale bar
is pictured)
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we observed that among postmenopausal women there was
a higher frequency of positive pIGF1R/pIR endometrial
glandular cell cytoplasmic IHC staining in diabetic as
compared with non-diabetic women. We also observed that
a larger proportion of postmenopausal OC users versus OC
nonusers had positive pIGF1R/pIR glandular cell nuclear
staining. A higher proportion of regular NSAID users had
positive staining for PR and IR than nonusers of NSAIDs.
Among premenopausal participants, we noted that a higher
frequency of ER-positive glandular cell staining in
endometrial tissues from parous women with C3 live births
versus 1–2 births and in PTEN-null versus wild-type
endometrium.
Our observation of a higher frequency of pIGF1R/pIR
endometrial tissue IHC staining in diabetic versus non-di-
abetic postmenopausal women could reflect the high levels
of insulin in circulation among diabetic women, or
increased bioactive IGF-I levels that might be induced by
the reduction of IGFBP1 in circulation due to insulin-re-
lated downregulation of IGFBP1 production. We caution
that this result was based on a small number of diabetic
women and this finding therefore requires confirmation in
larger studies that have the ability to examine insulin-re-
sistant women who have not yet developed diabetes and to
account for the possible effects of diabetes treatment on the
endometrium since this information was unavailable in the
current study. Nevertheless, this observation suggests a
mechanistic link between diabetes, an established risk
factor for endometrial cancer, and endometrial tumorige-
nesis. The pIGF1R/pIR pathway is of particular interest in
relation to endometrial cancer development, and at least
one previous study reported upregulation of pIGF1R/pIR in
complex atypical endometrial hyperplasia, a putative pre-
cursor lesion for endometrial cancer, as well as in grade 1
endometrial cancers as compared with normal endome-
trium [32]. In contrast, we observed that OC users, who are
expected to have a lower risk of developing endometrial
cancer, also had a higher frequency of positive pIGF1R/
pIR staining. It was notable that the pIGF1R/pIR glandular
cell staining localizations differed for the diabetes (cyto-
plasmic staining) and OC use (nuclear staining) results.
The cytoplasmic staining of pIGF1R/pIR in the endome-
trium of diabetic women is consistent with the well-char-
acterized function of IGF1R which is that it becomes
autophosphorylated upon ligand binding whereby its kinase
activity leads to phosphorylation of its downstream sub-
strates; subsequently, the activated receptor is internalized
to the cytoplasm and recycled to the membrane [34]. In
contrast, the role of nuclear pIGF1R/pIR is not well
established, and its functional implication remains uncer-
tain. However, the ability of the IGF1R and IR to
translocate to the nuclear compartment has been previously
reported [35]. The finding of a higher frequency of positive
pIGF1R/pIR nuclear staining in OC users and its possible
role in OC protection from endometrial cancer is a novel
finding that warrants further investigation. These studies
included a small number of postmenopausal endometrial
samples; thus, our analyses are exploratory and require
confirmation in additional studies.
In the current analysis, we observed that post-
menopausal NSAID users had higher endometrial expres-
sion of PR but not ER. These findings are of interest as a
Table 3 Immunohistochemical staining of insulin/IGF and sex hormone axes in premenopausal and postmenopausal endometrium
Protein Premenopausal (all subjects)
(n = 77)
Premenopausal (proliferative)
(n = 29)
Postmenopausal
(n = 29)
p valuea p valueb
ER (gland) 32/58 (55) 13/23 (57) 26/29 (90) 0.001 0.009
ER (stroma) 19/58 (33) 9/23 (39) 21/29 (72) 0.001 0.02
PR (gland) 20/24 (83) 8/9 (89) 26/28 (93) 0.40 1.00
PR (stroma) 19/23 (83) 8/9 (89) 22/28 (79) 1.00 0.66
IR-c (gland) 38/66 (58) 13/27 (48) 25/28 (89) 0.003 0.001
IR-c (stroma) 17/66 (26) 6/27 (22) 2/28 (7) 0.05 0.14
IGF1R-n (gland) 9/62 (15) 4/26 (15) 18/28 (64) \0.0001 \0.001
IGF1R-n (stroma) 11/62 (18) 5/26 (19) 10/28 (36) 0.10 0.23
pIGF1R/pIR-n (gland) 13/59 (22) 8/24 (33) 10/26 (38) 0.18 0.77
pIGF1R/pIR-n (stroma) 25/58 (43) 12/23 (52) 4/26 (15) 0.01 0.01
ER estrogen receptor alpha, IGF1R insulin-like growth factor 1 receptor, c cytoplasmic, n nuclear, pIGF1R/pIR phosphorylated IGF1R/
phosphorylated insulin receptor, IR insulin receptor
Numbers in table refer to n positive/n total (% positive)
Numbers may not sum to total due to missing data on immunohistochemical staining
a P value from Fisher’s exact test for the comparison of premenopausal (all subjects) versus postmenopausal
b P value from Fisher’s exact test for the comparison of premenopausal (proliferative phase subjects) versus postmenopausal
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recent meta-analysis of nine studies reported that any use
of aspirin NSAIDs versus no use of any type of NSAIDs
was associated with a 13 % lower risk of developing
endometrial cancer [9]. Higher PR levels would presum-
ably be protective for endometrial cancer development
wherein progesterone inhibits the proliferation of
endometrial epithelial cells via PR in stromal cells [36]. As
far as we are aware, this study was the first to investigate
NSAID use in relation to endometrial PR and ER levels;
these findings warrant further study as NSAID and similar
drug use is very common in this age group and might
contribute to their potentially protective influence on
endometrial cancer development. To our knowledge this
was the first study to report differences in IHC staining
patterns for pIGF1R/pIR with OC use and IR with NSAID
use in postmenopausal women, as well as differences in ER
staining by the number of live births and PTEN status in
premenopausal women. This was an exploratory study with
a limited number of tissue samples; therefore, the findings
may be due to chance and these results require confirma-
tion in additional studies.
It was notable that differences in IHC staining for
selected risk factors were only observed in postmenopausal
or premenopausal subjects but not across both subgroups.
Although the number of postmenopausal versus pre-
menopausal subjects was small, there were more significant
findings in postmenopausal women; this may be because
postmenopausal women are a more homogeneous group
with respect to their hormone levels, and all of these
women were nonusers of postmenopausal hormones. By
comparison, tissues from premenopausal women were
collected at different phases of the menstrual cycle and
several components of the insulin/IGF and sex hormone
axis vary by menstrual cycle phase as discussed below.
Due to the exploratory nature and small sample size of this
study, we cannot conclude that the findings are restricted to
only postmenopausal or premenopausal women and this
will require confirmation in further studies.
We also examined differences in key insulin/IGF and
sex hormone axis components in endometrial tissues by
menopausal status. In postmenopausal relative to prolifer-
ative phase premenopausal endometrium, there was a
higher proportion of positive ER, glandular IR, and IGF1R
IHC staining, and higher levels of IGFBP1 and IGFBP3
gene expression. In contrast, in proliferative phase pre-
menopausal endometrium there was a higher frequency of
positive pIGF1R/pIR staining (stromal cells only) and
higher IGF1 gene expression levels as compared with
postmenopausal tissues. Among premenopausal women,
compared with secretory phase endometrium, in prolifer-
ative endometrium we observed suggestive lower levels of
IGFBP1 and IGF2 mRNA, and a higher frequency of
positive glandular staining for the IR and pIGF1R/pIR
proteins. In agreement with the current report, previous
studies [37–39] observed higher expression of IGF1
mRNA in premenopausal (irrespective of menstrual cycle
phase) versus postmenopausal normal endometrium. On
the other hand, IGFBP1 and IGFBP3 levels were higher in
postmenopausal relative to premenopausal proliferative
endometrium in the current study, which to our knowledge
has not been previously published.
We observed a higher frequency of ER-positive staining
in postmenopausal versus premenopausal proliferative
endometrium and no difference in PR staining. The ER
result contrasts with previous reports of similar [40–42] or
lower frequencies of ER-positive staining [43] in post-
menopausal as compared with premenopausal proliferative
endometrium. The proportion of PR-positive glandular cell
staining (*90 % positive) in postmenopausal women in
the current study is in line with PR staining in a previous
report [44]. We could not identify prior studies that had
compared levels of the IR or IGF1R in postmenopausal
versus premenopausal women. In general, different results
across studies could be due to variability in IHC staining or
scoring methods, or possible differences in the proportion of
premenopausal endometrium sampled in early, mid, or late
menstrual cycle phases as this information was unavailable
in the current study. In particular, the latter issue may
influence results pertaining to genes that are thought to play
an important role in endometrial menstrual cycling (IGF1,
IGF2, and IGFBP1); for example, IGF1mRNA is expressed
preferentially in the mid-to-late proliferative and early
secretory phases, while IGF2 and IGFBP1 are expressed in
the mid-to-late secretory phase [45].
In contrast to earlier studies [42, 45–49], we did not
observe differences in IGF1 gene expression, or ER or PR
IHC staining, by menstrual cycle phase. In the pre-
menopausal endometrium, IGF1 mRNA is thought to be
estrogen-dependent, and increasing circulating estrogen
levels during the proliferative phase may stimulate IGF-I
production in the endometrial stromal cells that in turn
induces the proliferation of endometrial glandular tissue
[12, 45], reflected by the higher glandular pIGF1R/pIR
protein levels in proliferative phase endometrium. Con-
sistent with the current report, previous studies observed
higher IGF2 gene expression levels in secretory as com-
pared with proliferative phase endometrium [45, 46, 50].
Furthermore, our observation of higher IGFBP1 mRNA
levels in the secretory versus proliferative phase endome-
trium supports the suggestion that higher circulating pro-
gesterone levels during the secretory phase may stimulate
IGFBP1 mRNA expression [45, 46]. We did not observe
any variability in IGFBP3 gene expression according to the
menstrual cycle phase which contrasts with a previous
study that reported higher IGFBP3 mRNA levels in the
secretory versus proliferative phase [45].
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A potential limitation of our study was the small sample
size. Due to the limited sample size, we were unable to
adjust for age or other factors and therefore confounding
may be an issue. The current study also did not assess how
local tissue levels of the insulin/IGF and sex hormone
components relate to circulating levels because the small
sample size was a limiting factor in characterizing poten-
tially complex relationships between the serum peptide
levels and the tissue expression levels of mRNA and
proteins. However, the novel data generated in the current
study form a strong rationale and foundation for investi-
gating the relationship of serum and tissue markers in
future larger cohorts. Since a large number of statistical
tests were carried out, it is possible that some of the results
may be due to chance. Assay reproducibility was not
assessed in our study; however, IHC staining and qPCR
assays are routinely used and are considered reliable, and
quality control measures were used for both methods
Fig. 2 Gene expression of IGF axis genes in endometrium in relation
to menopausal status. Gene expression values (normalized to PPIB)
as detected by qPCR are pictured. Box and whisker plots depict the
median (line), interquartile range (box), and error bars demonstrate
the full range of the data
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(staining of positive and negative control tissues for IHC,
RNA passed rigorous quality control assessment and assays
were repeated in triplicate for qPCR). Women who have a
hysterectomy may have different endometrial tissue or
endometrial cancer risk factor distributions than the general
population which may limit the generalizability of these
findings. We did not validate our results in an independent
premenopausal or postmenopausal population; therefore,
the findings require confirmation in further studies.
Nonetheless, our study had several important strengths
including the systematic collection of fresh frozen and
paraffin-embedded tissues from both premenopausal and
postmenopausal women, and the linkage of epidemiologic
and clinical information with tissue insulin/IGF and sex
hormone expression levels which provides novel data on
the impact of several established endometrial cancer risk
factors on otherwise healthy endometrium.
In summary, we evaluated several major components of
the insulin/IGF and sex hormone axes in normal endome-
trial tissues from women without cancer in order to
describe their relationship with endometrial cancer risk
factors to further knowledge on potential biological
mechanisms. Among postmenopausal participants, we
observed higher pIGF1R/pIR levels in endometrial tissues
from diabetic versus non-diabetic women, which may
reflect the impact of high circulating insulin levels on
activation of these cancer-related receptors, and regular use
versus no use of NSAIDs was associated with a higher
expression of PR but not ER, which could be associated
with a lower endometrial cancer risk. Thus, the current
studies provide preliminary data pointing to mechanistic
factors that may contribute to early events in the multistage
process of endometrial carcinogenesis, with potential for
early disease prevention or risk stratification.
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